Altre lingue Galectin Therapeutics Inc.

Azioni

GALT

US3632252025

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 25/04/2024			Variaz. 5gg	Var. 1 gen.
3,5 ^USD	+6,38%		+3,55%	+110,84%

29/03	Galectin Therapeutics Inc. nomina Benjamin S. Carson come membro del Consiglio di Amministrazione	CI
29/03	Galectin Therapeutics Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Galectin Therapeutics : Corporate Presentation, April 2024	17/04
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension	10/04
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis	09/04
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update	01/04
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update	29/03
Galectin Therapeutics Inc. Appoints Benjamin S. Carson as Member of the Board of Directors	29/03
Galectin Therapeutics : Reports 2023 Financial Results and Provides Business Update - Form 8-K	29/03
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
North American Morning Briefing : Stocks Set for -2-	28/03
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development	12/03
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update	13/11
Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
North American Morning Briefing : Stock Futures -2-	13/11
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD	03/11
Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023	23/10/23
Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors	12/10/23
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension	04/10/23
Galectin Says Data and Safety Monitoring Board Approves Continuation of Belapectin Study Without Modifications.	03/10/23
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis	03/10/23
Galectin Therapeutics, Inc. Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE	03/10/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Galectin Therapeutics Inc.

Azioni

GALT

US3632252025

Altre lingue

Filtri